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Essential oils are secondary metabolites with a key-role in plants protection, consisting primarily of terpenes with a volatile nature
and a diverse array of chemical structures. Essential oils exhibit a wide range of bioactivities, especially antimicrobial activity, and
have long been utilized for treating various human ailments and diseases. Cancer cell prevention and cytotoxicity are exhibited
through a wide range of mechanisms of action, with more recent research focusing on synergistic and antagonistic activity between
specific essential oils major and minor components. Essential oils have been shown to possess cancer cell targeting activity and
are able to increase the efficacy of commonly used chemotherapy drugs including paclitaxel and docetaxel, having also shown
proimmune functions when administered to the cancer patient. The present review represents a state-of-the-art review of the
research behind the application of EOs as anticancer agents both in vitro and in vivo. Cancer cell target specificity and the use
of EOs in combination with conventional chemotherapeutic strategies are also explored.
1. Introduction
Whilst some synthetic compounds unequivocally have an
important role in disease prevention and therapy, there is
also an extensive collection of naturally existing compounds
that have been exploited for their unique medicinal purposes
[1]. The use and demand of natural compounds have been
increasing worldwide, showing their importance, which can
be attributed to relevant medicinal properties [2]. Essential
Oils (EOs) and other phytoproducts are examples of natural
products that have gained interest, mainly due to their
suitable chemical characteristics and biological activities [3].
As stationary organisms, plants have evolved a diverse
range of protective mechanisms to lessen their vulnerability
against external threats. These mechanisms can be classified
as physical and chemical defenses. Physical deterrents include
protective structural characteristics, which include waxy
barriers, spikes, and “hair-like” trichomes, which release
chemical compounds [4]. Chemical defense mechanisms
include, for example, the production of a range of defen-
sive metabolites bioactive compounds with the capability
to repulse herbivores or even to target their endocrine
and nervous system [5, 6]. These include EOs, enzymes,
tannins, and flavonoids, amongst others. Importantly, these
compounds are also of pharmacological interest.
EOs are complex and multifunctional substances with
plant origin, which have been used for thousands of years for
their role in the prevention and treatment of various ailments
[3, 7, 8]. Chemically, EOs are aromatic plants secondary
metabolites with several roles: defense against herbivores,
insects, and microorganisms; communication with plants of
the same species; and signalingwithin the plant in response to
environmental stimuli [5]. As each plant species or subspecies
has evolved to protect itself from a particular predator or
group of predators, each plant produces its own specific “sig-
nature” mixture of EO chemical constituents [5, 7]. This can
contain from 20 to 60 constituents at varying concentrations,
with two or three primary constituents (20–70%) [9, 10].
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Figure 1: Chemical structures of essential oil constituents.
1.1. Chemical Composition of EOs. There are approximately
3000 EOs, from over 2000 different plants, with around
300 EOs possessing known biomedical features [2, 10, 11].
Together with the plant species, the developmental stage
(flowering, fruiting) and aromatic compound extraction
methods have a direct influence on the composition of EOs,
which explains the variability of components in the reported
EOs [12].
Based on their chemical compositions, EOs are broadly
categorized into oxygenated compounds and hydrocar-
bons [9]. Oxygenated compounds include esters, aldehydes,
ketones, alcohols, phenols, and oxides. Other active groups
include aromatics and sulfur-containing components [9–
12, 24]. Hydrocarbon compounds are composed of one
specific chemical group called terpenes (Figure 1) [9]. These
are composed of varying numbers of isoprene units (C
5
).
Monoterpenes (C
10
) and sesquiterpenes (C
15
) are the main
terpenes, although the isoprene chainsmay also include diter-
penes (C
20
). Monoterpenes contribute to 90% of EO overall
constituents [9]. Bothmonoterpenes and sesquiterpenes offer
a large variety of structures through adjoining with other
biologically active functional groups (monoterpenoids), and
chemical rearrangement and addition of oxygenated groups
(sesquiterpenoids) [9]. Terpenes may also be acyclic, mono-
cyclic, or bicyclic andmay contain an aromatic group [9].The
longer the isoprene chain, the more the chemical variations
possible [9, 24]. The structures of several medicinally impor-
tant terpenes are illustrated in Figure 1.
Due to the large range and complex blend of EOs
constituents, as well as their many functional groups, it is
thought that EOs do not possess a specific single cellular
target, with each complex mixture initiating different cellular
effects through their major constituents [9, 10]. However,
it is important to consider the minor constituents of an
EO, and the different cellular effects exhibited when the
constituents are combined in the EO blend versus the iso-
lated constituents. A study performed by Santana-Rios and
coworkers (2001) isolated themain constituents of both white
and green tea and created an artificial “mixed” tea with a
total of 9 main constituents [25]. The artificial tea exhibited a
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lesser antimutagenic effect than the whole tea extracts in the
Salmonella assay in the presence of 𝑁-hydroxy-IQ, a potent
mutagen. Furthermore, it has been shown that EOs extracted
from the tea tree, eucalyptus, and thyme plants reduced
Herpes simplex virus- (HSV-) 1 viral infectivity by more than
96% in an in vitro study through inactivation of virus-free
particles, with the combined EO constituents more effective
than the isolated counterparts [26]. Recent studies also have
been pointing out the therapeutic potential of the individual
constituents of EOs, such as the work of Dias and colleagues
(2017), which showed a possible association between the
oxygenated monoterpenes of EOs extracted from Lavandula
luisieri and Cymbopogon citratus and the antifungal activity
against dermatophytes [27]. This was because an inhibitory
effect was observed on the conidial germination, demonstrat-
ing the strong antifungal activity of these EOs components
[27]. The mentioned studies indicate that minor constituents
possess both synergistic and antagonistic activities on the
major constituents, playing an important role in the overall
properties of EOs on a variety of cell types.
1.2. EOs as Therapeutic Agents. Only 5 to 15% higher order
plants have been addressed for their bioactive compounds
[28]. As EOs are a coevolutionary product of plants, func-
tioning to protect them from herbivore attack, they often
elicit undesirable and potentially harmful effects on animal
cells and bodily functions [5]. However, these undesirable
effects of EOs can be exploited and used to treat diseases
and symptoms. Examples include emetics and laxatives,
muscle relaxants, cardiac stimulants, and cardiac depressants
resulting in hypotension and induction of bradycardia [8].
Atherosclerosis is the arterial build-up of fats and other
compounds and is a large contributor to thrombosis and
arterial occlusion [29]. The main driver of this disease is
the oxidation of low-density lipoproteins (LDLs), and it was
shown that phenolic-rich EOs such as thymol and eugenol
exhibit the highest LDL antioxidative effect, with their capa-
bilities increased through also reducing LDLs’ affinity for the
LDL receptor [7]. Other benefits for treating cardiovascular
disease, thus reducing the risk of atherosclerosis, include the
reduction of cholesterol and triglyceride levels in plasma,
in which black cumin oil achieved this reduction in rats
over a period of 12 weeks, with low toxicity and no adverse
effects in kidneys or liver [7]. Additionally, recent studies have
demonstrated the capability of EOs to act on inflammatory
and other cellular processes associated with cardiovascular
diseases, by preventing the secretion of proinflammatory
factors through the reduction of lipopolysaccharide (LPS)
[30, 31]. EOs may be used in both analgesics and anti-
inflammatories, such as black cumin and eucalyptus oils [32,
33]. It is clear, with respect to recent research, that Eos’ ability
to bind various cellular receptors has therapeutic value and
potential for both treatment of infectious diseases, and for
inborn and intrinsic diseases. Importantly, thesemechanisms
of action of EOs leading to cellular and metabolic responses
make them attract new sources of anticancer therapeutic
strategies.
The aim of this review is to evaluate the research behind
the application of EOs as anticancer agents, both in vitro and
in vivo. Cancer cell target specificity without noncancerous
tissue toxicity will be explored, as well as the use of EOs in
combination in conventional chemotherapeutic strategies.
2. Anticancer Proprieties of EOs
According to the International Agency for Research on Can-
cer (IARC), in 2012 there were 14.1 million new cancer cases
worldwide and 8.2 million cancer deaths [34]. Cancer is now
the leading cause of death and is expected to increase by 70%
in the next two decades, with lung, liver, stomach, colorectal,
breast, prostate, and oesophageal cancer accounting for most
of the deaths [34, 35]. These statistics support the need for
new and novel chemotherapeutic drugs in the coming years.
Cancer is broadly divided into three stages: (1) initiation,
in which cellular DNA damage and mutation occur on
carcinogen exposure and due to failure of DNA repair
mechanisms; (2) promotion, in which hyperproliferation,
tissue remodelling, and inflammation occur due to expansion
of initiated cell/s; and (3) progression, in which preneo-
plastic cells form tumors through clonal expansion, further
facilitated by an increase in genomic instability and altered
gene expression [36]. The different stages of carcinogenesis
require different chemotherapeutic approaches, due to the
evolutionary nature of cancer, which lead to alterations in
sensitivity to therapy. Specifically, tumour progression is
associated with genomic instability, through accumulation of
mutations for factors involved in cell proliferation, apoptosis,
and DNA repair, amongst others [36, 37]. Chemotherapy
drugs act on the promotion stage, in ways including cellular
proliferation inhibition, increased rate of cell death, and
induction of tumor cell differentiation [38].
Although research on the application of EOs as anticancer
therapeutic agents is relatively new, approximately half of
conventional chemotherapy agents have plant origin, with
roughly 25% directly derived from plants, and 25% being
chemically modified versions of phytoproducts [28]. One
such molecule is paclitaxel. Paclitaxel (of which the most
common brand name is Taxol) was originally derived from
the bark of the tree Taxus brevifolia [39]. Its mechanism of
action is based on the induction of a mitotic arrest via the
targeting of the cytoskeleton component tubulin, resulting in
mitotic checkpoint activation, and subsequent apoptosis [39].
It is used as a therapeutic agent either as a single agent or
in combination therapy strategies for various cancer types,
including ovarian, breast, and pancreatic cancer [39]. Labora-
tory synthesis of this drug was needed due to depletion of the
natural source, primarily through a synthesis route involving
EO constituent patchoulol (Figure 1) to produce patchoulol
oxide [40]. More recently, Altshuler and collaborators found
that the enantiomer (+)-citronellal, a major component of
Corymbia citriodora and Cymbopogon nardus EOs, is also
an effective microtubule-disrupting compound, similarly to
better-known microtubule-disrupting agents colchicine and
vinblastine [41].
EOs have been shown to possess anticancer properties
through various mechanisms, including cancer preventative
mechanisms, as well as acting on the established tumor cell
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Figure 2: Essential oils cancer preventative and anticancer mechanisms of action. EOs possess antimutagenic, antiproliferative, antioxidant,
and detoxifying capabilities acting on various pathways in the cancer cell as well as cancer preventative capabilities. EOs may directly inhibit
mutagen entry into the cell. EOs can decrease phase I enzymes such as CytC, preventing mutagen formation, and increase phase II enzymes
such as GST, UGT, QR, and EH for enhanced detoxification. EOs bind ROS forming reactive phenoxy radicals which bind further ROS
and increase antioxidative enzymes CAT, SOD, GPx, and GSH thus preventing oxidative damage as a cancer preventative mechanism. EOs
disrupt mitochondrial membrane potential causing an increase in ROS and decrease in GSH, release of CytC, resulting in a cascade of
disruption in Bcl/Bax ratio, increase in caspase 3 and caspase 9 activity, and PARP cleavage, resulting in apoptosis. EOs suppress mTOR
and pPDK1 causing PKB dephosphorylation, which dually acts to initiate caspase activity and deactivate mdm2, causing an increase in p21 to
further initiate caspase activity resulting in apoptosis. Increased p21 also induces G1/S phase cell cycle arrest. EOs cause a decrease in CDK7,
blocking CDK1/cyclin complex causing G2/M phase cell cycle arrest. Bax: B-cell lymphoma 2-associated X protein; Bcl-2: B-cell lymphoma
2; CAT: catalase; CDK: cyclin-dependant kinase; CytC: cytochrome C; CytP450: cytochrome P450; EH: epoxide hydrolase; EO: essential oil;
ER: endoplasmic reticulum; ETC: electron transport chain; GPx: glutathione peroxidase; GSH: glutathione; GST: glutathione S-transferase;
mdm2: murine double minute 2; mTOR: mechanistic target of rapamycin; MITO: mitochondria; NF𝜅B: nuclear factor-𝜅B; PARP: poly ADP
ribose polymerase; pPDK1: protein pyruvate dehydrogenase kinase 1; PKB: protein kinase B; QT: quinone reductase; ROS: reactive oxygen
species; SOD: superoxide dismutase; UGT: uridine 5󸀠-diphospho-glucuronosyltransferase.
itself and interaction with the microenvironment (Figure 2)
[7, 42].
2.1. Antimutagenic Proprieties and Detoxification Enhance-
ment. EO cancer preventative mechanisms include direct
inhibition of the mutagen entering the cell, although under-
lying mechanisms remain unexplained [7, 43]. Other can-
cer preventives and antimutagenic properties include a
decrease of enzymes involved in drug metabolism. These
include phase I enzymes such as cytochrome P450 [44,
45]. Phase II enzymes are responsible for detoxification
and are mainly comprised of transferases [46]. Glutathione
𝑆-transferase (GST), uridine 5󸀠-diphospho-glucuronosyl-
transferase (UGT), quinone reductase (QR), and epoxide
hydrolase (EH) were observed to be increased on sulfur-
containing EO activity such as that from garlic and onions
[47–52]. The EO component citral, a monoterpene obtained
from plants such as lemongrass, has been shown to induce
phase II enzymes in a dose-dependent manner [53]. The
mechanism of action of citral is due to its geranial iso-
form component [53]. Recent studies have shown citral to
inhibit cell proliferation and tumor growth by increasing
the intracellular levels of oxygen radicals and, consequently,
inducing oxidative stress, leading to reduction of cancer cell
proliferation and ultimately resulting in cell death [54, 55].
2.2. Antiproliferative Mechanisms of Action of EOs. Key
hallmarks of cancer include resisting cell death, sustained
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proliferative signaling, and evading growth suppressors [28].
Therefore, therapeutic strategies focused on inducing apop-
tosis and cellular arrest are of clear significance. EOs have
been shown to induce both the intrinsic (or mitochondria-
dependent) and extrinsic (or death receptor-dependent)
apoptosis pathways.
Girola and coworkers (2015) tested the antitumor prop-
erties of a camphene isolated from the EO of Piper cernuum
in melanoma cells. The study demonstrated that this com-
pound was able to induce apoptosis through the caspase-
3 pathway activation, as well as activating the endoplasmic
reticulum (ER) stress signaling [56]. Another study focused
on the evaluation of the mechanism of action of carvacrol,
a phenolic monoterpenoid abundant in the EOs of oregano
and thyme [57]. In the metastatic breast cancer cell line
MDA-MB-231, carvacrol induced apoptosis via mitochon-
drial membrane permeabilization, resulting in cytochrome C
release, induction of caspases indicated through poly ADP
ribose polymerase (PARP) cleavage, and DNA fragmentation
[57]. Frankincense extracts obtained from Boswellia sacra
induced PARP cleavage with apoptosis in MDA-MB-231
cells, with higher cancer cell specificity [14]. Citral was also
shown to induce caspase activation and subsequent apoptosis
induction in several cancer cell types, including colorectal
cancer and glioblastoma [58–60]. Other studies have shown
that citral treatment can lead to reduction of expression
of prostemness and prosurvival factors such as aldehyde
dehydrogenase 1A3 (ALDH1A3) and microtubule affinity
regulating kinase 4 (MARK4) in cancer, respectively [61, 62].
PKB (Protein kinase B) is a key molecule with roles
regarding cellular metabolism, transcription, cell cycle pro-
gression, and survival [63]. The vapor of Litsea cubeba seed
oil induced cell cycle arrest and apoptosis of nonsmall cell
lung carcinoma cells, a cancer type with a high mortality rate
[64]. In this study, apoptosis occurred due to a significant
decline in the expression of mTOR (mechanistic target of
rapamycin) protein, and a decline in the phosphorylating
ability of PPDK1 (protein pyruvate dehydrogenase kinase
1), leading to dephosphorylation of PKB and initiating the
caspase-dependent apoptosis pathway [64]. Furthermore,
PKB dephosphorylation inactivated mdm2 (murine double
minute 2), leading to an increase in p21 expression, and
subsequent caspase initiation after G1/S phase arrest [64].
This dualmechanism offers antiproliferative as well as antiox-
idant proprieties, and the vapor can be inhaled directly to
the site of cancer in the lung, offering a clear advantage in
administration [64].
Wu and colleagues showed that administering organosul-
phur components of garlic significantly decreased cell via-
bility (𝑃 =< 0.05) compared with control in a dose and
time-dependent manner, with diallyl trisulphur being the
most effective [65]. This was observed in J5 liver tumor cell
line through a G2/M cycle arrest, leading to cell death via a
decrease in expression of cyclin-dependent kinase (CDK) 7
and subsequent CDK1/cyclin complex inhibition [65].
Expression of NF𝜅B (nuclear factor-𝜅B) is abnormally
increased in cancer cells and is particularly associated
with cancer initiation and progression [66–68]. 𝛼-terpineol,
a monoterpenoid alcohol, was able to downregulate the
transcription of NF𝜅B in a range of tumor cells, with the
strongest inhibitory effect on small cell lung carcinoma cell
line NCI-H69 [69]. Finally, 𝛼-terpineol was further shown to
have synergistic propertieswith anothermonoterpene, linalyl
acetate, in colon cancer cells, inhibiting NF𝜅B expression and
resulting in apoptosis [70].
2.3. Antioxidant Proprieties of EOs. Mitochondrial DNA
damage can result from oxidative stress, and defects on the
electron transport chain (ETC) result in the further release
of reactive oxygen species (ROS) and further DNA, lipid,
and protein damage [71]. Antioxidant properties of EOs
can, therefore, contribute to cancer preventative mechanisms
[36, 72]. Specific EO components such as eugenol, the main
constituent extracted from clove oil, can react with ROS to
form reactive phenoxy radicals, which can then combine
with further ROS and prevent further damage [73]. Other
cancer protective mechanisms induced by EOs include the
induction of the expression of antioxidant enzymes such as
catalase, superoxide dismutase, glutathione peroxidase, and
glutathione, as shown by Manjamalai and Berlin Grace [74].
Treatment with EO extracts ofWedelia chinensis (96% of the
components being carvacrol and trans-caryophyllene) lead to
an increase in intracellular antioxidant activity, subsequently
leading to a significant reduction in tumor mass volume as
well and regeneration of surrounding healthy tissue [74].
However, research by Le Gal and colleagues (2015)
showed that increased intracellular antioxidant activities can
actually increase tumor cell survival, both using in vitro and in
vivo models [75]. Specifically, oxidized glutathione, an indi-
cator of oxidative stress levels, was increased on antioxidant
administration, thus offering protection for the melanoma
metastasis cancer cells [75]. This is a similar mechanism
as the one observed with conventional chemotherapy drug
methotrexate, which is a prooxidant and increases cellular
glutathione levels [76]. Therefore, EO extracts with these
types of antioxidant properties are likely to bemore beneficial
as chemopreventive agents for nontumor tissue.
Finally, Legault and colleagues (2000) showed that balsam
fir oil extracts led to decreased glutathione levels,mediated by
the EO component gamma-caryophyllene, which promotes
ROS increase and glutathione decrease due to 𝛼-humulene
in a dose-dependent manner [77].
3. Cancer Cell Specificity of Essential Oils
Conventional chemotherapy drugs aremore cytotoxic to can-
cer cells due to their higher rate of cell division; however, due
to this mechanism of action, there are issues with tumor cell
specificity and associated cytotoxicity to healthy cells [78].
The subsequent side effects in the patient can hinder recovery
and even prove to be life-threatening. Currently, combined
therapeutic approaches of surgery followed by chemotherapy,
radiotherapy, and immunotherapy offer increased chances
of treating cancer and remission [78]. However, this does
not address the need for cancer cell-specific therapy, or an
increased therapeutic window between normal and cancer
cells. Novel targeted strategies are a significant improvement
but still have issueswith cell specificity, andmore importantly,
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a very high attrition whenmoving these agents from preclini-
cal studies to clinical applications [78].Theuse ofmonoclonal
antibodies is highly selective, though it has limited cytotoxic
activity [79]. Combined administration of monoclonal anti-
bodies and conventional chemotherapy drugs is one potential
route for solving this problem, delivering the highly cytotoxic
agent specifically to cancer cells [79].
The use of EOs extracts as single agents has been shown
in various in vitro studies to specifically target cancer cells,
with absent or markedly less cytotoxicity exhibited towards
healthy cells with a range of mechanisms of action (Table 1).
Boswellia sacra extracts have shown very promising
results in vitro and in vivo. Boswellia sacra extracts were
shown to be cytotoxic to three breast cancer cell lines (T47D,
MCF7, and MDA-MB-231) at varying concentrations, which
were noncytotoxic to immortalized normal human breast
cells MCF10-2A [14]. This study also showed that Boswellia
sacra extracts that were hydrodistilled for 12 hours at 100∘C
were more potent than the essential oil extracts prepared at
78∘C, with a higher amount of boswellic acid present. Apop-
tosis markers activated caspase 3 activity, PARP cleavage,
and DNA fragmentation rapidly in MDA-MB-231 but not
MCF10-2A cells [14]. Importantly, treatmentwith the extracts
blocked the growth of multicellular tumor spheroids from
T47D, indicating the potential for efficacy in in vivo models
[14]. Similarly, Boswellia sacra showed cell-specific cytotox-
icity in a dose-dependent manner to bladder transitional
cell carcinoma cell line J82, in contrast to no cytotoxicity
observed in normal bladder cell line UROtsa [17]. Treatment
of J82 cells rapidly led to cell shrinkage and detachment from
the plate, whereas no changes were observed for UROtsa
cells. This effect was associated with decreased expression
of 47 genes after treatment with the EO extracts, whose
functions include transcription factors, cell cycle regulation,
and cell proliferation [17]. Finally,Boswellia sacra also showed
cytotoxicity towards human pancreatic cells, both cultured
and in a xenograft mouse model, exhibiting repression of
cell cycle regulators and activation of the caspase pathway
in in vitro cultures, and causing decreased tumor cell growth
and tumor cell death in vivo [80]. Similarly, to the work by
Suhail et al. (2011) [14], EO extract potency was increased
with the increase of hydrodistillation temperature, associated
with the extraction of higher levels of boswellic acids and
sesquiterpenes, which is indicated to be positively correlated
with cytotoxicity [80].
EO extracts from Amomum tsaoko exhibited cytotoxicity
towards various human cancer cell lines, including liver
cancer (HepG2 and Bel-7402), cervical cancer (HeLa), gastric
adenocarcinoma (SGC-7901), and prostate cancer (PC-3)
[15]. Importantly, these extracts were less effective towards
normal hepatocytes HL-7702 and umbilical vein endothelial
(HUVEC) cell lines [15]. The individual components of this
EO mixture, eucalyptol and geraniol, were also tested [15].
Eucalyptol was not cytotoxic to any cancer cell line, and
geraniol exhibited a minimal cytotoxic effect towards all
cancer cell lines but was markedly lower than the complete
EO mixture [15]. Synergism of eucalyptol and geraniol with
each other and/or other EO components, therefore, must
contribute to the cytotoxic activity [15].
4. Synergism of EO Extracts with Conventional
Chemotherapeutic Agents: Potential of
Combination Therapy Using EOs
Specific EO constituents have been shown to enhance the
cytotoxic activity of chemotherapy drugs in various cell lines
(Table 2), thus increasing the therapeutic window, that is,
lowering the required drug concentrations whilst providing
the same effect [22, 23].
Docetaxel is the first line therapy for hormone-refractory
prostate cancer, which has a median survival of 20 months
[22]. Docetaxel is associated with serious side effects and
is currently used in combination with treatment exhibiting
dose-dependent toxicity to the patient [22]. 𝑑-limonene
showed cytotoxic activity alone towards prostate cancer cell
line DU-145, and when administered alongside docetaxel,
sensitized the cells towards this drug in a dose-dependent
manner allowing for a markedly lower dose of docetaxel to
be used, achieving the IC
50
in concentrations from 2.8 nM
to 1.9mM [22]. Limited toxicity was also shown towards
normal prostate epithelial cells. Further analysis on the effects
of combined treatment showed an increase in ROS produc-
tion from both mitochondrial dependent and independent
pathways, as well as increased cytochrome C release, p53
stabilisation, and caspase and PARP cleavage after 0-48 hours
[22]. In addition to decreasing the amount of toxic docetaxel
required, d-limonene showed low toxicity towards humans.
It is possible that this combination may also be effective in
docetaxel-resistant cell lines [22].
𝛽-caryophyllene, which was not cytotoxic as a single
agent, was shown to markedly increase the cytotoxic activity
of paclitaxel in various cancer cell lines (Table 2). Specifi-
cally, the largest effect was observed on DLD-1 cells treated
with paclitaxel combined with 10 𝜇g/mL−1𝛽-caryophyllene,
increasing paclitaxel activity approximately 10 times [23].
It was shown that 𝛽-caryophyllene increased cell mem-
brane permeability for paclitaxel uptake, likely due to 𝛽-
caryophyllene accumulation in the lipid bilayer, and thus
altering the permeability for substances such as paclitaxel
[23].
Neutropenia is a common side effect of both cancer itself
and therapies including chemotherapy and radiotherapy, the
latter especially if targeted to active sites of bone marrow
proliferation [81]. Cancer-related neutropenia has a high
mortality rate due to susceptibility to infectious diseases,
particularly from gram-negative bacterial infections, and
combined with fever is considered an oncological emer-
gency [81]. Currently, there are limited adjunctive treatments,
one of which is the administration of granulocyte colony-
stimulating factors (G-CSFs), in selected patients only,
which promotes bone marrow production of granulocytes
[81]. Alternatively, chemotherapy dose-modification may be
deemed appropriate [81]. A study by Zhuang and coworkers
(2009) which included 105 cancer patients with nonterminal
breast, colorectal, nasopharyngeal, or lung cancer showed
significant results in preventing the depletion of leukocytes
(14.2%) and neutrophils (11%), versus control (29.1%) over
a 6-week period [82]. Flow cytometry analysis showed a
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larger depletion of CD4 and natural killer cells in the placebo
receiving group versus the Chinese medicinal herb complex
(CCMH) receiving group [82]. The largest component of
the CCMH was the EO component citronellol (273.6mg
per capsule), a known strong antioxidative compound, also
exhibiting anticancer and anti-inflammatory properties, as
well as promoting wound healing [82]. It is not clear from
this study how exactly citronellol and each other component
contributed to results. So, to date the mechanism of action
remains to be elucidated.
Geraniol has been shown previously to sensitize can-
cer cells to the conventional chemotherapeutic agent 5-
fluorouracil (5-FU), also causing an increased uptake of
the drug [83, 84]. Geraniol has also been shown to be
chemoprotective towards normal colon cells in rats when
administered with the potent carcinogen dimethylhydrazine
[85]. This effect occurs through mediating the reduction of
DNA damage when compared with controls where no EO
extract was used [85].
5. Conclusions and Future Directions
EO have been shown to possess a wide range of anticancer
properties andmechanisms. Considering the myriad of com-
ponents present and the mechanism and synergistic capabili-
ties of EO extracts, it is of paramount importance to perform
further studies regarding evaluation on how EO minor
components contribute to the overall effect of the EO extract
mixture. Further in vitro and in vivo research into achieving
the most effective cytotoxic EO mixture composition would
allow for more targeted therapy, and with increased speci-
ficity to cancer cells over non-cancer tissue. Furthermore, the
currently used concentrations of conventional chemotherapy
drugs could potentially be reduced combined with specific
EO, which could also decrease chemotherapy-associated
toxicity. Moreover, synthetic modification of these molecules
may allow improving their overall efficacy further. However,
there is still a significant lack of preclinical studies for EOs as
anticancer agents; thus many EOs require further safety and
toxicity studies before they can take part in clinical trials.
Cancer cell specificity is a sought-after propriety that is
lacking in conventional chemotherapeutic strategies [79, 86].
As well as addressing cellular specificity, another strategy to
increase cell specificity includes novel drug delivery strategies
[86]. Specifically, a new field addressing this involves the
use of microspheres made of proteins or synthetic polymers
containing the anticancer agent or EO, for delivery to the
specific organ or another site of cancer [86]. These can be
administered intravenously or intra-arterially depending on
the target site [86]. The use of microspheres has promising
potential due to multiple types of drugs being success-
fully contained and delivered in a single vehicle, offering
the potential for combination therapies, but also, the use
of nanoemulsions is an improvement to transport and to
deliver the EOs with anticancer properties, improving their
therapeutic effect [87]. Cancer cell specificity can also be
enhanced by the use of ligands added to the surface, targeting
overexpressed cell surface proteins on the cancer cell [88].
Crucially, EOs can be degraded through physical, chemical,
or enzymatic processes, so microsphere encapsulation may
prevent this for optimised delivery [88, 89]. This way, EOs
and other drugs may be released in a controlled manner,
potentially reducing excess dosage and increasing the overall
safety of these constituents, and offering a promising strategy
for targeted drug and EO delivery to cancer cells [89].
In conclusion, although this is a relatively new and
emerging area of cancer research, the ability of EOs and their
components of having such diverse anticancer effect through
acting on various pathways and cellular mechanisms is com-
pelling. Thus, it is warranted that more studies be performed
to expand the present knowledge of these mechanisms with
the aim of promoting cell-specific and individualized cancer
therapy.
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